The latest onvansertib data, and an abrupt CEO departure, spook investors.
ApexOnco Front Page
Recent articles
BioNTech will test the bispecific in two new lung indications.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Arcellx and AstraZeneca take centre stage.
